Sionna Therapeutics (SION) Cash from Investing Activities (2024 - 2026)

Sionna Therapeutics has disclosed Cash from Investing Activities across 3 years of filings, most recently posting $24.8 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $24.8 million, up 117.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $47.3 million (up 132.78% YoY), and the FY2025 annual result was -$118.7 million, up 6.43% from the prior year.
• Cash from Investing Activities came in at $24.8 million for Q1 2026 at Sionna Therapeutics, up from $22.6 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $24.8 million in Q1 2026 to a low of -$141.2 million in Q1 2025.
• The 3-year median for Cash from Investing Activities is $10.4 million (2024), against an average of -$24.5 million.
• Peak annual rise in Cash from Investing Activities reached 121.99% in 2025, while the deepest fall reached 13.93% in 2025.
• Sionna Therapeutics' Cash from Investing Activities stood at $15.2 million in 2024, then surged by 48.33% to $22.6 million in 2025, then increased by 9.88% to $24.8 million in 2026.
• The last three Cash from Investing Activities figures came in at $24.8 million (Q1 2026), $22.6 million (Q4 2025), and $23.1 million (Q3 2025), per Business Quant data.